$PFNX on NYSE AMERICAN
August 06, 2020
Pfenex Reports Second Quarter 2020 Results and Provides Business Update
July 20, 2020
Pfenex to Announce Second Quarter Financial Results on August 6
June 26, 2020
Pfenex Announces Positive European CHMP Opinion for PF708 (EU Brand Name: Livogiva™) and New Partnership in Latin America, and Provides CRM197 Business Update
June 12, 2020
Pfenex Announces U.S. Commercial Launch of Teriparatide Injection
June 05, 2020
Pfenex to Participate in the William Blair Growth Stock Conference
May 07, 2020
Pfenex Reports First Quarter 2020 Results and Provides Business Update
April 24, 2020
Pfenex to Announce First Quarter 2020 Financial Results on May 7
April 14, 2020
Pfenex Announces FDA Requests Additional Comparative Use Human Factors Data in Experienced Users in order to Complete PF708 Therapeutic Equivalence Determination
March 11, 2020
Pfenex Reports Fourth Quarter and Full Year 2019 Results and Provides Business Update
February 26, 2020
Pfenex to Announce Fourth Quarter and Year-End 2019 Financial Results on March 11
January 08, 2020
Serum Institute of India Private Limited has achieved World Health Organization (WHO) prequalification for PNEUMOSIL®, containing CRM197 produced in Pfenex Expression Technology
December 18, 2019
Pfenex Earns $15 Million Development Milestone Under its Development and License Agreement With Jazz Pharmaceuticals
November 20, 2019
Pfenex to Present at the Piper Jaffray 31st Annual Healthcare Conference
November 19, 2019
Pfenex to Present at the Evercore ISI HealthCONx Conference 2019
November 13, 2019
Pfenex Announces Management Change
November 07, 2019
Pfenex Reports Third Quarter 2019 Results and Provides Business Update
November 06, 2019
Pfenex to Present at the Jefferies 2019 London Healthcare Conference
October 24, 2019
Pfenex to Announce Third Quarter 2019 Financial Results on November 7th
October 14, 2019
Pfenex Reports Positive Results for PF708 Comparative Use Human Factors Study
October 11, 2019
Pfenex Provides Update for PF708 Outside the United States
October 07, 2019
Pfenex Receives U.S. FDA Approval for PF708 to Treat Osteoporosis
September 16, 2019
Pfenex to Present at the Cantor Healthcare Conference
September 10, 2019
Pfenex to Participate in the Oppenheimer Fall Summit
September 05, 2019
Pfenex Earns $11 Million Development Milestone under its Development and License Agreement with Jazz Pharmaceuticals
September 04, 2019
Pfenex Appoints Dr. Steve Kay to Scientific Advisory Board
August 08, 2019
Pfenex Announces Appointment of New Board Member, Lorianne Masuoka, M.D.
August 01, 2019
Pfenex and Arcellx Announce a Development, Evaluation and License Agreement
July 25, 2019
Pfenex to Announce Second Quarter 2019 Financial Results on August 8
June 05, 2019
Pfenex to Participate at the JMP Securities Life Sciences Conference
May 30, 2019
Pfenex and Alvogen Announce European Medicines Agency Accepts Marketing Authorization Application for PF708
May 09, 2019
Pfenex Reports First Quarter 2019 Results and Provides Business Update
April 25, 2019
Pfenex to Announce First Quarter 2019 Financial Results on May 9
April 23, 2019
Pfenex Appoints Dr. Robert Peach to Scientific Advisory Board
April 11, 2019
Pfenex Announces Successful Expiration of 45 Day Waiting Period Under Hatch-Waxman Act
March 27, 2019
Pfenex to Participate at the William Blair Late-Stage Therapeutics Conference
March 26, 2019
Pfenex to Present at the 18th Annual Needham Healthcare Conference
March 18, 2019
Pfenex to Present at the 29th Annual Oppenheimer & Co. Healthcare Conference
March 18, 2019
Pfenex Appoints Dr. Martin B. Brenner as Chief Scientific Officer
March 11, 2019
Pfenex Reports Fourth Quarter and Full Year 2018 Results and Provides Business Update
March 06, 2019
Pfenex Licensee Successfully Completes a Phase 3 Study and Enters Registration for Pneumosil®
March 04, 2019
Pfenex Announces Appointment of New Board Member, Magda Marquet, Ph.D.
February 28, 2019
Pfenex and Alvogen Expand Development and Commercialization Collaboration for PF708, a Therapeutic Equivalent Candidate to Forteo®/Forsteo®, to the EU, MENA, and ROW
February 27, 2019
Pfenex to Participate at Two Investor Conferences in March
February 25, 2019
Pfenex to Host Conference Call and Webcast Reporting Fourth Quarter Financial Results on Monday, March 11th
February 19, 2019
Pfenex Announces FDA Acceptance of NDA for PF708
- No Recent Filings Found.
